Xu Chuanshan, Law Siu Kan, Leung Albert Wing Nang
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Department of Food and Health Sciences, The Technological and Higher Education Institute of Hong Kong, Tsing Yi, New Territories, Hong Kong.
Pharmaceuticals (Basel). 2024 May 21;17(6):663. doi: 10.3390/ph17060663.
UNLABELLED: Photodynamic therapy (PDT) is a minimally invasive treatment for several diseases. It combines light energy with a photosensitizer (PS) to destroy the targeted cells or tissues. A PS itself is a non-toxic substance, but it becomes toxic to the target cells through the activation of light at a specific wavelength. There are some limitations of PDT, although it has been used in clinical studies for a long time. Two-photon excitation (TPE) and upconversion (UC) for PDT have been recently developed. A TPE nanoparticle-based PS combines the advantages of TPE and nanotechnology that has emerged as an attractive therapeutic agent for near-infrared red (NIR) light-excited PDT, whilst UC is also used for the NIR light-triggered drug release, activation of 'caged' imaging, or therapeutic molecules during PDT process for the diagnosis, imaging, and treatment of cancers. METHODS: Nine electronic databases were searched, including WanFang Data, PubMed, Science Direct, Scopus, Web of Science, Springer Link, SciFinder, and China National Knowledge Infrastructure (CNKI), without any language constraints. TPE and UCNP were evaluated to determine if they had different effects from PDT on cancers. All eligible studies were analyzed and summarized in this review. RESULTS: TPE-PDT and UCNP-PDT have a high cell or tissue penetration ability through the excitation of NIR light to activate PS molecules. This is much better than the conventional PDT induced by visible or ultraviolet (UV) light. These studies showed a greater PDT efficacy, which was determined by enhanced generation of reactive oxygen species (ROS) and reduced cell viability, as well as inhibited abnormal cell growth for the treatment of cancers. CONCLUSIONS: Conventional PDT involves Type I and Type II reactions for the generation of ROS in the treatment of cancer cells, but there are some limitations. Recently, TPE-PDT and UCNP-PDT have been developed to overcome these problems with the help of nanotechnology in in vitro and in vivo studies.
未标注:光动力疗法(PDT)是针对多种疾病的一种微创治疗方法。它将光能与光敏剂(PS)相结合以破坏目标细胞或组织。光敏剂本身是一种无毒物质,但通过特定波长的光激活后会对目标细胞产生毒性。尽管光动力疗法已在临床研究中使用了很长时间,但仍存在一些局限性。最近已开发出用于光动力疗法的双光子激发(TPE)和上转换(UC)技术。基于TPE纳米颗粒的光敏剂结合了TPE和纳米技术的优势,已成为用于近红外(NIR)光激发光动力疗法的一种有吸引力的治疗剂,而上转换也用于近红外光触发的药物释放、“笼形”成像的激活或光动力疗法过程中用于癌症诊断、成像和治疗的治疗分子的激活。 方法:检索了九个电子数据库,包括万方数据、PubMed、Science Direct、Scopus、Web of Science、Springer Link、SciFinder和中国知网(CNKI),无任何语言限制。对TPE和上转换纳米颗粒(UCNP)进行评估,以确定它们对癌症的作用是否与光动力疗法不同。本综述对所有符合条件的研究进行了分析和总结。 结果:通过近红外光激发以激活PS分子,TPE光动力疗法(TPE-PDT)和UCNP光动力疗法(UCNP-PDT)具有较高的细胞或组织穿透能力。这比由可见光或紫外线(UV)诱导的传统光动力疗法要好得多。这些研究显示出更高的光动力疗法疗效,这由活性氧(ROS)生成增加、细胞活力降低以及抑制癌细胞异常生长来确定。 结论:传统光动力疗法在治疗癌细胞时通过I型和II型反应产生活性氧,但存在一些局限性。最近,已开发出TPE-PDT和UCNP-PDT,以在体外和体内研究中借助纳米技术克服这些问题。
Theranostics. 2013-3-25
Nanomaterials (Basel). 2018-5-18
Chem Soc Rev. 2016-10-5
Nanoscale Adv. 2021-2-24
Front Chem. 2022-11-17
Acta Biomater. 2017-3-15
Photodiagnosis Photodyn Ther. 2021-12
J Nanobiotechnology. 2023-8-19
Nanomaterials (Basel). 2023-5-3
Biomed Opt Express. 2023-1-9
Cancers (Basel). 2023-1-18